|
|
|
Volumn 1, Issue 4, 2003, Pages 237-
|
|
ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2).
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
GEFITINIB;
MONOCLONAL ANTIBODY;
QUINAZOLINE DERIVATIVE;
TRASTUZUMAB;
ARTICLE;
BIOSYNTHESIS;
BREAST TUMOR;
CHEMISTRY;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
HUMAN;
METASTASIS;
PATHOLOGY;
PATIENT SELECTION;
PHASE 2 CLINICAL TRIAL;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL PROTOCOLS;
HUMANS;
NEOPLASM METASTASIS;
PATIENT SELECTION;
QUINAZOLINES;
RECEPTOR, ERBB-2;
|
|
EID: 33644626501
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|